Ting-Tse Lin1,2, Wei-Shun Yang3, Mu-Yang Hsieh1,2, Chih-Chen Wu1, Lian-Yu Lin2,4. 1. Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu. 2. Department of Internal Medicine, National Taiwan University College of Medicine, Taipei. 3. Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu. 4. Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: Left ventricular hypertrophy (LVH) is prevalent in patients with end-stage renal disease (ESRD), and may be secondary to arterial stiffness and volume overload. It is unclear whether LVH is caused by autonomic nerve dysregulation (AND), a frequent condition in patients with ESRD that is characterized by sympathetic hyperactivity and vagal withdrawal. We hypothesized that AND estimated by heart rate variability (HRV) may be associated with LVH in patients with ESRD. METHODS: We prospectively enrolled patients with ESRD undergoing hemodialysis. Cardiac function and LVH were assessed using echocardiography according to the recommendations of the American Society of Echocardiography. Holter recordings were used to quantify HRV and deceleration capacity (DC). Dataon comorbidities and medications, and serum markers were obtained. Logistic regression analysis was performed. RESULTS: Among the 281 included patients, 63% had LVH. The patients with LVH were older, had more comorbidities and advanced diastolic dysfunction than those without LVH. The root mean square of successive differences (rMSSD) (9.10 ± 5.44 versus 13.25 ± 8.61; p = 0.004) and DC (2.08 ± 1.90 versus 3.89 ± 1.45; p = 0.021) were lower in the patients with LVH than that in those without LVH. Multivariate regression analysis showed that hypertension, asymmetrical dimethylarginine (ADMA), advanced diastolic dysfunction grade, rMSSD, and DC were independently associated with LVH. Among these variables, DC and ADMA showed the highest diagnostic value for LVH with areas under curves of 0.701 and 0.751, respectively. CONCLUSIONS: AND is independently associated with LVH in patients with ESRD.
BACKGROUND: Left ventricular hypertrophy (LVH) is prevalent in patients with end-stage renal disease (ESRD), and may be secondary to arterial stiffness and volume overload. It is unclear whether LVH is caused by autonomic nerve dysregulation (AND), a frequent condition in patients with ESRD that is characterized by sympathetic hyperactivity and vagal withdrawal. We hypothesized that AND estimated by heart rate variability (HRV) may be associated with LVH in patients with ESRD. METHODS: We prospectively enrolled patients with ESRD undergoing hemodialysis. Cardiac function and LVH were assessed using echocardiography according to the recommendations of the American Society of Echocardiography. Holter recordings were used to quantify HRV and deceleration capacity (DC). Dataon comorbidities and medications, and serum markers were obtained. Logistic regression analysis was performed. RESULTS: Among the 281 included patients, 63% had LVH. The patients with LVH were older, had more comorbidities and advanced diastolic dysfunction than those without LVH. The root mean square of successive differences (rMSSD) (9.10 ± 5.44 versus 13.25 ± 8.61; p = 0.004) and DC (2.08 ± 1.90 versus 3.89 ± 1.45; p = 0.021) were lower in the patients with LVH than that in those without LVH. Multivariate regression analysis showed that hypertension, asymmetrical dimethylarginine (ADMA), advanced diastolic dysfunction grade, rMSSD, and DC were independently associated with LVH. Among these variables, DC and ADMA showed the highest diagnostic value for LVH with areas under curves of 0.701 and 0.751, respectively. CONCLUSIONS: AND is independently associated with LVH in patients with ESRD.
Entities:
Keywords:
Deceleration capacity; ESRD; Left ventricle hypertrophy; Vagal withdrawal
Authors: Jan W Kantelhardt; Axel Bauer; Aicko Y Schumann; Petra Barthel; Raphael Schneider; Marek Malik; Georg Schmidt Journal: Chaos Date: 2007-03 Impact factor: 3.642
Authors: Christopher T Chan; Glenn M Chertow; John T Daugirdas; Tom H Greene; Peter Kotanko; Brett Larive; Andreas Pierratos; John B Stokes Journal: Nephrol Dial Transplant Date: 2013-09-26 Impact factor: 5.992
Authors: Lindsay J Chesterton; Nicholas M Selby; James O Burton; Jana Fialova; Cian Chan; Chris W McIntyre Journal: Hemodial Int Date: 2009-11-03 Impact factor: 1.812
Authors: C Kurata; A Uehara; T Sugi; A Ishikawa; K Fujita; K Yonemura; A Hishida; K Ishikawa; K Tawarahara; S Shouda; T Mikami Journal: Nephron Date: 2000-04 Impact factor: 2.847
Authors: Friedrich Schulze; Reinhard Wesemann; Edzard Schwedhelm; Karsten Sydow; Jennifer Albsmeier; John P Cooke; Rainer H Böger Journal: Clin Chem Lab Med Date: 2004 Impact factor: 3.694
Authors: Christopher T Chan; Tom Greene; Glenn M Chertow; Alan S Kliger; John B Stokes; Gerald J Beck; John T Daugirdas; Peter Kotanko; Brett Larive; Nathan W Levin; Ravindra L Mehta; Michael Rocco; Javier Sanz; Phillip C Yang; Sanjay Rajagopalan Journal: Clin J Am Soc Nephrol Date: 2013-08-22 Impact factor: 8.237